scholarly journals Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia

2012 ◽  
Vol 140 (7-8) ◽  
pp. 448-455
Author(s):  
Milena Bozic ◽  
Ksenija Bojovic ◽  
Milotka Fabri ◽  
Darko Nozic ◽  
Bojan Trkulja ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Multicenter Trial ◽  
Multivariable Logistic Regression Analysis ◽  
Hcv Rna ◽  
Efficacy And Safety ◽  
Specific Pcr ◽  
Adverse Affects

Introduction. Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. Pegylated interferon alfa-2a or 2b (PEG IFN alfa-2a or 2b) and ribavirin (RBV) represent a standard treatment of chronic hepatitis C (CHC). Sustained virological response (SVR), defined as continued undetectable HCV RNA 24 weeks after completion of treatment, is universally considered as an indicator of treatment efficacy. Objective. The aim of this study was to determine efficacy and safety of PEG IFN alfa-2a and RBV treatment in patients with CHC in Serbia. Methods. One hundred seventy-six patients with CHC were included in this multicenter trial from 8 reference centers in Serbia. The patients were treated with standard PEG IFN alfa- 2a and RBV protocol. We performed the following virological testing: anti-HCV (ELISA), HCV RNK (quantitative PCR), HCV genotype (type-specific PCR), HBsAg, anti-HBs, anti-HBc and anti-HIV (ELISA). Histological activity and the degree of fibrosis were determined according to the Metavir scoring system. Potential predictors for achieving SVR were evaluated using multivariable logistic regression analysis. Results. Of the treated patients with CHC 65.9% were male, and 60.2% of them aged over 40 years. Of the treated patients 68.2% had infection over 5 years, 63% had HCV RNA >400.000 IU/mL, 76.1% had HCV G1/4, and 60.1% had a mild to moderate liver fibrosis. SVR was achieved in 78.9% of patients (G1/4 79.1%; G2/3 78.1%). The factors that indicated a poorer efficacy of the treatment were age >40 (p<0.05), high basal viremia (p=0.013), and the reduction of PEG IFN alfa-2a and RBV doses, with interruption of therapy (p<0.001). Of the treated patients 45.9% had adverse affects (G1/4 50.8%; G2/3 29.7%). Conclusion. Treatment of CHC with PEG IFN alfa-2a and RBV was efficient in 78.9% of patients. The safety profile of therapy was satisfactory. Longer therapy increases the possibility of the development of adverse affects. No life-threatening adverse effects were recorded in our patients.

scholarly journals Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients

2006 ◽  
Vol 22 (4) ◽  
pp. 315-320 ◽  
Author(s):  
Miguel Santin ◽  
Evelyn Shaw ◽  
M. Jose Garcia ◽  
Antonio Delejido ◽  
Eduardo Rodriguez De Castro ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Efficacy And Safety ◽  
Interferon Α2b

scholarly journals Efficacy and safety of pegylated interferon α-2b and ribavirin in chronic hepatitis C in children

2010 ◽  
Vol 6 ◽  
pp. 341-348
Author(s):  
Joanna Kupś-Rzepecka ◽  
Violetta Gołąbek ◽  
Przemysław Kiciński ◽  
Teresa Woźniakowska-Gęsicka
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Interferon Α ◽  
Efficacy And Safety

Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C

2011 ◽  
Vol 16 (5) ◽  
pp. 771-774
Author(s):  
Robert Roomer ◽  
Anneke J van Vuuren ◽  
Martin Schutten ◽  
Angela Heijens ◽  
Harry LA Janssen ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Interferon Α ◽  
Hcv Rna

scholarly journals Efficacy and safety of сepeginterferon alfa-2b in the rteatment of chronic hepatitis c in outpatients.

2018 ◽  
Vol 95 (11) ◽  
pp. 1022-1025
Author(s):  
Alexander V. Mamonov ◽  
R. A. Mamonov
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Pegylated Interferon ◽  
Efficacy And Safety ◽  
Results Of Treatment ◽  
Previously Treated ◽  
Outpatient Practice ◽  
High Degree

The features of the application of pegylated interferon - Сepeginterferon alfa2b (cepeg-IFN) on the results of treatment of 20 patients with chronic hepatitis C in outpatient practice. The analysis of the clinical, biochemical, virological data and transient liver elastometry on the background of antiviral therapy with cepeg-IFN. Based on these data is justified is not the worst in comparison with foreign analogues the efficacy and safety of the original domestic product for the treatment of patients with chronic hepatitis C, not previously treated with antiviral therapy, without a high degree of fibrosis or cirrhosis. Demonstrated clinical example of treatment failure associated with infection with a recombinant virus 2k1b and proposes an approach to the diagnosis of this variant infection

High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3219-3219
Author(s):  
Maria E. Mancuso ◽  
Elena Santagostino ◽  
Maria G. Rumi ◽  
Silvia Linari ◽  
Antonio Coppola ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Side Effects ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Univariate Analysis ◽  
Pegylated Interferon ◽  
Hcv Rna ◽  
Genotype 2

Abstract Pegylated interferon (Peg-IFN) plus ribavirin is the standard treatment for patients with chronic hepatitis C. In a multicenter open trial, we assessed the efficacy and tolerability of this treatment in 78 HIV negative hemophiliacs (age: 20–64 years) with persistently high transaminase values. Sixty-four were naïve and 14 were relapsers to IFN monotherapy. Cirrhosis was clinically detected in 12 patients (15%). HCV genotype was 1 in 69%, 2a/c in 14%, 3a in 14% and 4 in 3%. Peg-IFN alpha-2b was given subcutaneously at doses of 1.5 mcg/Kg/week for 48 weeks in genotypes 1 and 4 and for 24 weeks in genotypes 2 and 3; oral ribavirin at 800–1200 mg/day based on body weight. Treatment was stopped in patients with polymerase chain reaction positive HCV-RNA at month 6. Results: 11 patients (14%) withdrew for side effects (4) or non-compliance (7). Neutropenia (&lt;500 cells/mmc), decompensated diabetes, ALT flares, and vomiting not responding to antiemetic drugs were reasons for treatment discontinuation. The median fall in hemoglobin levels was 3.1 g/dL. Weight loss (38%), fatigue (33%) and cephalalgia (15%) were frequent side effects. Thirty-two patients (41%) required dose reduction of ribavirin (23, 29%) or Peg-IFN (20, 26%). At the end of the 6-month follow-up, sustained virological response (SVR) was achieved in 43 patients (55%): 40/64 naïve (63%) and 3/14 relapsers (21%, p = 0.007). Five patients (6%), all relapsers to IFN monotherapy, had a virological breakthrough during treatment and 4 (5%) relapsed during the post-treatment follow-up period. SVR was obtained in 86% genotypes 2/3 and 43% genotypes 1/4 (p = 0.001). Predictors of SVR were evaluated by univariate analysis in the 64 naïve patients. SVR was significantly associated with HCV infection type 2 and 3 (86% vs 50% in HCV type 1 and 4; p = 0.008), absence of cirrhosis (97.5% vs 75% in non-responders; p = 0.02) and higher pre-treatment serum ALT levels (111 vs 75 IU/L in non-responders; p = 0.02). SVR rates did not differ in relation to patient’s age, pretreatment HCV viremia, median disease duration and compliance to full-dose treatment. Conclusions: combination therapy with Peg-IFN plus ribavirin is the recommended therapeutic option for hemophiliacs with hepatitis C chronic infection. Relapsers to IFN monotherapy may benefit of re-treatment with Peg-IFN plus ribavirin achieving at least 20% SVR. Genotype 2 and 3 infection is the most significant predictor of SVR.

Sign in / Sign up

Export Citation Format

Share Document